Statera Biopharma, Inc. Share Price Nasdaq
Equities
STAB
US8575611046
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0007 USD | 0.00% | 0.00% | -99.98% |
2023 | Statera Biopharma, Inc. entered into a letter of intent to acquire Worksite Labs. | CI |
2023 | Statera Biopharma, Inc.(OTCPK:STAB) dropped from S&P TMI Index | CI |
Sales 2020 | - | Sales 2021 | 1.49 118.98 | Capitalization | 73.82M 5.91B |
---|---|---|---|---|---|
Net income 2020 | -12M -960M | Net income 2021 | -102M -8.16B | EV / Sales 2020 * | - |
Net Debt 2020 | 1.41M 113M | Net Debt 2021 | 14.28M 1.14B | EV / Sales 2021 | 59,246,379 x |
P/E ratio 2020 * |
-
| P/E ratio 2021 |
-0.79
x | Employees | 46 |
Yield 2020 * |
-
| Yield 2021 |
-
| Free-Float | 100% |
Current month | -99.98% | ||
Current year | -99.98% |
Managers | Title | Age | Since |
---|---|---|---|
Yakov Kogan
FOU | Founder | 50 | 04/06/03 |
Andrei V. Gudkov
FOU | Founder | 66 | 04/06/03 |
Michael Handley
CEO | Chief Executive Officer | 52 | 26/07/21 |
Members of the board | Title | Age | Since |
---|---|---|---|
John A. Kallassy
BRD | Director/Board Member | 59 | 01/09/22 |
Uday Saxena
BRD | Director/Board Member | 66 | 16/06/22 |
Michael Handley
CEO | Chief Executive Officer | 52 | 26/07/21 |
Date | Price | Change | Volume |
---|---|---|---|
07/05/24 | 0.0007 | 0.00% | 60,767 |
06/05/24 | 0.0007 | 0.00% | 13,255 |
03/05/24 | 0.0007 | 0.00% | 479 |
02/05/24 | 0.0007 | +∞% | 2,711 |
30/04/24 | - | -100.00% | 51 |
Delayed Quote Nasdaq, May 07, 2024 at 07:33 pm
More quotes1st Jan change | Capi. | |
---|---|---|
+21.74% | 46.81B | |
-0.97% | 41.37B | |
+47.07% | 41.29B | |
-3.52% | 28.87B | |
+11.12% | 26.06B | |
-19.37% | 19.13B | |
+31.18% | 12.39B | |
-0.04% | 12.08B | |
+0.39% | 11.96B |
- Stock Market
- Equities
- STAB Stock
- STAB Stock